We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sandoz, recently announced that it has entered into an agreement with Gan & Lee Pharmaceutical to commercialize biosimilar versions of insulins used in patients with type 1 and type 2 diabetes.